Protein microarray-based comparison of HER2, estrogen receptor, and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues.
Berg D, Langer R, Tran K, Walch A, Schuster T, Bronger H, Becker KF
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to compare HER2, ER, and PR protein expression in core biopsies and surgical excision specimens using RPPA. Additionally, RPPA results were compared with IHC results. FISH was used to further evaluate HER2 status of specimens scored as 2+ by IHC.
Summary of Findings
Absolute concordance rates between surgical specimens and core biopsies were 91.4% for HER2, 80% for ER, and 82.8% for PR. For HER2, 1/35 specimens was classified as HER2+ in the surgical specimen but HER2- in the core biopsy, while 2/35 specimens were HER2- in the surgical specimen but HER2+ in the core biopsy. For ER, 1/35 specimens was classified as ER+ in the surgical specimen but ER- in the core biopsy, while 6/35 specimens were ER- in the surgical specimen but ER+ in the core biopsy. For PR, 4/35 specimens were classified as PR+ in the surgical specimen but PR- in the core biopsy, while 2/35 specimens were PR- in the surgical specimen but PR+ in the core biopsy. Concordance rates of 100% and 94.2% were seen between RPPA and IHC for surgical specimens and core biopsies, respectively.
Biospecimens
TissueBreastPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
ProteinReverse phase protein microarrayProteinImmunohistochemistryDNAFISHPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Method of tissue acquisition Core needle biopsySurgical resectionFISH Specific Targeted nucleic acid HER2Immunohistochemistry Specific Targeted peptide/protein ERHER2PRReverse phase protein microarray Specific Targeted peptide/protein ERHER2PRReverse phase protein microarray Specific Technology platform Immunohistochemistry